Valeant Pharmaceuticals International
NEWS
Valeant Pharmaceuticals International was acquired by Bausch & Lomb in 2013.
Scandals are nothing new in any industry. The pharmaceutical and biotech industry are certainly no strangers to scandals – just ask convicted scandal-magnet Martin Shkreli.
Patients are discovering that Teva’s generic isn’t really that much cheaper than Valeant Pharmaceutical’s branded drug to treat Wilson’s Disease.
Valeant’s CEO projects that a $1 billion portfolio of key products will help the drug maker fight debt and exclusivity challenges.
Just before ringing in the new year, Valeant has managed to resolve another crisis.
From around 2014 through 2016, Valeant seemingly had a crisis story per week, ranging from insider trading to channel stuffing
Should you invest the way billionaire investors do?
As 2017 comes to a close, 40 drugs have been approved so far, with the record being in 2015, when 46 drugs were approved.
Valeant is not the only company to recently push reporters to defy the SEC’s orders.
A little more than two years after acquiring Sprout, Valeant is selling off the developer of the female sex drive drug Addyi.
IN THE PRESS